Fibrinogen predicts mortality in high risk patients with peripheral artery disease

被引:44
作者
Doweik, L [1 ]
Maca, T [1 ]
Schillinger, M [1 ]
Budinsky, A [1 ]
Sabeti, S [1 ]
Minar, E [1 ]
机构
[1] Univ Vienna, Sch Med, Dept Angiol, Vienna, Austria
关键词
fibrinogen; atherosclerosis; mortality;
D O I
10.1016/S1078-5884(03)00340-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Fibrinogen plays a key role in the pathogenesis of atherosclerosis and complications of atherothrombotic disease. We investigated the prognostic impact of fibrinogen levels on mortality of high risk patients with peripheral artery disease (PAD). Methods: We studied 486 patients with PAD and several cardiovascular comorbidities. Atherosclerotic risk factors and fibrinogen levels were determined at initial presentation and patients were followed for median 7 years (IQR 6-10)for allcause and cardiovascular mortality. Multivariate Cox regression analysis was applied to assess the predictive value of fibrinogen levels (in quartiles) on patients' outcome. Results: Cumulative survival rates at 1, 3, 5 and 10 years were 96, 91, 83 and 67%, respectively. Overall, 138 patients (28%) died, 70% of these patients died of cardiovascular complications (n = 96). Patients with fibrinogen levels 10.2-12.2 mumol/l (third quartile) and patients with fibrinogen levels above 12.2 mumol/l (fourth quartile) had a significantly increased adjusted risk for all-cause mortality (hazard ratios [HR] 1.87 and 1.90, p = 0.025 and p = 0.020, respectively) compared to patients in the lowest quartile (fibrinogen below 8.6 mumol/l). A consistent effect was observed for cardiovascular causes of death. Diabetes mellitus and critical limb ischemia were the only other independent predictor variables (HR 2.08, p < 0.001 and 1.88, p = 0.001, respectively). Conclusion: Elevated fibrinogen levels in high risk patients with PAD indicate an increased risk for poor outcome, particularly for fatal cardiovascular complications.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 22 条
[1]   Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic [J].
Acevedo, M ;
Pearce, GL ;
Kottke-Marchant, K ;
Sprecher, DL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (06) :1042-1045
[2]   Novel clinical markers of vascular wall inflammation [J].
Blake, GJ ;
Ridker, PM .
CIRCULATION RESEARCH, 2001, 89 (09) :763-771
[3]   Adhesion of activated platelets to endothelial cells:: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), αvβ3 integrin, and GPIbα [J].
Bombeli, T ;
Schwartz, BR ;
Harlan, JM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (03) :329-339
[4]   Systematic review on the risk and benefit of different cholesterol-lowering interventions [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :187-195
[5]   Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - Meta-analyses of prospective studies [J].
Danesh, J ;
Collins, R ;
Appleby, P ;
Peto, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1477-1482
[6]  
DEJANA E, 1988, INTERACTION PLATELET, V1, P197
[7]   Elevated white blood cell count and carotid plaque thickness - The Northern Manhattan Stroke Study [J].
Elkind, MS ;
Cheng, JF ;
Boden-Albala, B ;
Paik, MC ;
Sacco, RL .
STROKE, 2001, 32 (04) :842-849
[8]   FIBRINOGEN AS A CARDIOVASCULAR RISK FACTOR - A METAANALYSIS AND REVIEW OF THE LITERATURE [J].
ERNST, E ;
RESCH, KL .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (12) :956-963
[9]   FIBRINOGEN [J].
ERNST, E .
BRITISH MEDICAL JOURNAL, 1991, 303 (6803) :596-597
[10]   Prospective study of hemostatic factors and incidence of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study [J].
Folsom, AR ;
Wu, KK ;
Rosamond, WD ;
Sharrett, AR ;
Chambless, LE .
CIRCULATION, 1997, 96 (04) :1102-1108